Search | Clinical Trials Finder

Conditions: Healthy Volunteer
Interventions: ACHN-975, placebo; Drug
Lead sponsor: Achaogen, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteer, Renal Impairment
Interventions: PF-06700841; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Edgewater, Florida • Miami, Florida • Orlando, Florida + 2 more

Conditions: Psoriasis
Interventions: VTP-43742, Placebo 1, Placebo 2; Drug
Lead sponsor: Vitae Pharmaceuticals Inc., an Allergan affiliate; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Rogers, Arkansas • Miami, Florida • Tampa, Florida + 9 more

Conditions: Major Depressive Disorder, Excessive Sleepiness
Interventions: GATE-101; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Acne Vulgaris
Interventions: Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Broomall, Pennsylvania

Conditions: Hepatic Impairment
Interventions: Tavapadon; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions: XmAb7195, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peyronie's Disease
Interventions: H-100, Placebo; Drug
Lead sponsor: Hybrid Medical; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Robbinsdale, Minnesota

Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions: ATTO-1310, ATTO-1310 Placebo; Drug
Lead sponsor: Attovia Therapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Encinitas, California • Rocklin, California • Sacramento, California + 7 more

Conditions: Bacterial Infections
Interventions: QPX9003 for IV Infusion, Placebo for IV infusion; Drug
Lead sponsor: Qpex Biopharma, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: S-equol, Placebo; Drug
Lead sponsor: Ausio Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Toxicity
Interventions: N-Methanocarbathymidine, Placebo Capsule; Drug · Other
Lead sponsor: N&N Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Eye Pain
Interventions: Loteprednol Etabonate Ophthalmic Gel; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 6
States / cities: Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more

Conditions: Renal Impairment, Healthy Volunteers
Interventions: Bocidelpar; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Anniston, Alabama • Rialto, California • Miami, Florida + 1 more

Conditions: Hepatic Insufficiency
Interventions: Mavorixafor; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Montclair, California • Rialto, California • Orlando, Florida + 1 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: AZD5055, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Influenza
Interventions: FGI-101-1A6; Drug
Lead sponsor: Functional Genetics Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breakthrough Pain
Interventions: Inhaled Placebo, Inhaled Fentanyl 25 mcg, Intravenous Fentanyl 25 mcg, Inhaled Fentanyl 25 mcg x 2, Inhaled Fentanyl 25 mcg x 4, Inhaled Fentanyl 25 mcg x 6, Inhaled Fentanyl 25 mcg x 12; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteers, Hepatic Impairment
Interventions: BMS-986435; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Chandler, Arizona • Miami Lakes, Florida • San Antonio, Texas

Conditions: Breast Cancer
Interventions: AZD9496 (Reference), AZD9496 Variant A, AZD9496 Variant B, AZD9496 Variant C, AZD9496 Variant D; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Arthritis, Rheumatoid
Interventions: SKI-O-703 capsule, Placebo capsule; Drug
Lead sponsor: Oscotec Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Anesthesia
Interventions: One spray CTY-5339-A, One spray CTY-5339-CB, Two sprays CTY-5339-A, One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo); Combination Product · Drug
Lead sponsor: Cetylite Industries; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

Renal Impairment Study of PF-06700841

A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Peyronie's Disease Treatment Protocol

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)

Staccato Fentanyl Single and Multidose PK

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers

Study of Attention Deficit/Hyperactivity Disorder Using Transcranial Magnetic Stimulation